Journal article
F-18-fluciclovine PET-CT and Ga-68-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial
Jeremie Calais, Francesco Ceci, Matthias Eiber, Thomas A Hope, Michael S Hofman, Christoph Rischpler, Tore Bach-Gansmo, Cristina Nanni, Bital Savir-Baruch, David Elashoff, Tristan Grogan, Magnus Dahlbom, Roger Slavik, Jeannine Gartmann, Kathleen Nguyen, Vincent Lok, Hossein Jadvar, Amar U Kishan, Matthew B Rettig, Robert E Reiter Show all
The Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2019
Abstract
BACKGROUND: National Comprehensive Cancer Network guidelines consider 18F-fluciclovine PET-CT for prostate cancer biochemical recurrence localisation after radical prostatectomy, whereas European Association of Urology guidelines recommend prostate-specific membrane antigen (PSMA) PET-CT. To the best of our knowledge, no prospective head-to-head comparison between these tests has been done so far. The aim of this study was to compare prospectively paired 18F-fluciclovine and PSMA PET-CT scans for localising biochemical recurrence of prostate cancer after radical prostatectomy in patients with low prostate-specific antigen (PSA) concentrations (<2·0 ng/mL). METHODS: This was a prospective, si..
View full abstractGrants
Awarded by Fondation ARC pour la recherche sur le cancer
Awarded by US Department of Energy
Awarded by Prostate Cancer Foundation
Awarded by Johnson Comprehensive Cancer Center National Institutes of Health-National Cancer Institute Cancer Center
Awarded by National Institutes of Health (NIH)
Awarded by Deutsche Forschungsgemeinschaft (Bonn, Germany)
Awarded by German Research Foundation (Deutsche Forschungsgemeinschaft)
Awarded by National Institutes of Health
Funding Acknowledgements
We thank all the patients and their referring physicians whose willingness to participate made this study possible. We thank the whole staff team of the University of California Los Angeles (UCLA; Los Angeles, CA, USA) Nuclear Medicine and Theranostics Division whose hard work made this study possible. This was an investigator-initiated trial with institutional academic funding (Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA). JCa was the recipient of a grant from the Philippe Foundation Inc. (New York, NY, USA) and from the Fondation ARC pour la recherche sur le cancer (grant SAE20160604150). FC was supported by a Postdoctoral Fellowship Award from the Fondazione Umberto Veronesi (post-doctoral travel-grant 2018). JCz was the recipient of a grant from the US Department of Energy (DE SC0012353), from the Prostate Cancer Foundation (2017 Challenge Award, 17CHAL02), and from the Johnson Comprehensive Cancer Center National Institutes of Health-National Cancer Institute Cancer Center Support Grant (P30 CA016042). TAH was supported by the Prostate Cancer Foundation (2017 Jonathan Kovler Young Investigator Award) and the National Institutes of Health (NIH, grant R01CA212148). ME was supported by the SFB 824 (DFG Sonderforschungsbereich 824, Project B11) from the Deutsche Forschungsgemeinschaft (Bonn, Germany). WPF was the recipient of a scholarship from the German Research Foundation (Deutsche Forschungsgemeinschaft grant 807122), the University of Duwasburg-Essen IFORES programme, the Doktor Robert Pfleger-Stiftung, and the Wiedenfeld-Stiftung. MSH was supported by a Clinical Fellowship Award from the Peter MacCallum Foundation. HJ was supported in part by the National Institutes of Health grants (numbers R21-EB017568 and P30-CA014089).